Acute Myeloid Leukemia (AML) remains a formidable clinical challenge, predominantly due to the emergence of resistance to existing therapeutic regimens, including BCL‐2 inhibitors like Venetoclax. Here, BCL2 is linked to acute myeloid leukemia.